ArticleSleep & breathing = Schlaf & Atmung2026
GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTirzepatide, a GLP-1 receptor agonist (GLP-1RA), is the first approved medication for the treatment of moderate to severe OSA and has previously been found to reduce cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). Our study analyzed the effects of GLP-1RA in preventing cardiovascular and pulmonary complications in patients with OSA and T2DM during a 5-year follow-up period.
methodsThrough the TriNetX database, patients with OSA and T2DM from 2010-2022 were included. We compared patients receiving GLP-1RA versus other diabetic medications including metformin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylurea, and thiazolidinedione. Using a propensity score model, participants were matched on a range of demographic and clinical factors. Patients were evaluated for cardiovascular and pulmonary outcomes using a Kaplan-Meier survival analysis. We additionally analyzed the incidence rate of ED visits and inpatient admissions.
resultsAfter matching, 5,750 to 21,065 patients were included in the GLP-1RA versus other diabetes medication groups. GLP-1RA showed a lower risk of acute respiratory failure compared to metformin (HR 0.89; 95%CI 0.80-0.98), DPP-4 inhibitors (HR 0.78; 95%CI 0.71-0.85), sulfonylureas (HR 0.70; 95%CI 0.64-0.76) and TZD (HR 0.76; 95%CI 0.65-0.89). GLP-1RA group demonstrated significantly lower risk of pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and heart failure when compared to DPP-4 inhibitors, sulfonylureas, and TZD.
conclusionGLP-1RA use was associated with a lower risk of pulmonary complications including acute respiratory failure, pulmonary hypertension, and COPD as well as lower ED visits and inpatient admissions compared to other diabetes medications. Further prospective studies are needed to evaluate the benefits of GLP-1RA.
Indexed as
Identifiers
42363996What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.